Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Qualigen Therapeutics, Inc. QLGN
$0.97
-$0.07 (-6.73%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
4568151.00000000
-
week52high
6.50
-
week52low
0.83
-
Revenue
4983556
-
P/E TTM
0
-
Beta
0.01311900
-
EPS
-4.61000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Abdul-Ahad Wajdi | A | 80000 | 80000 | 11 июл 2022 г. |
| Sinha Shishir K. | A | 100000 | 100000 | 11 июл 2022 г. |
| Korenberg Matthew E | A | 40000 | 40000 | 11 июл 2022 г. |
| BROIDRICK AMY S. | A | 130000 | 130000 | 11 июл 2022 г. |
| Poirier Michael S. | A | 375000 | 375000 | 11 июл 2022 г. |
| David Richard A. | A | 40000 | 40000 | 11 июл 2022 г. |
| Lotz Christopher L. | A | 100000 | 100000 | 11 июл 2022 г. |
| Kruger Kurt H | A | 40000 | 40000 | 11 июл 2022 г. |
| ARSHAD TARIQ | A | 102000 | 102000 | 11 июл 2022 г. |
| EMERY SIDNEY W JR | A | 40000 | 40000 | 11 июл 2022 г. |
Новостная лента
Qualigen Therapeutics to Present at BIO International Convention
GlobeNewsWire
14 июн 2022 г. в 09:00
CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics will present a corporate overview at the BIO International Convention to be held on June 13 – 16, 2022 at the San Diego Convention Center.
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
GlobeNewsWire
20 мая 2022 г. в 09:15
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL and virtually.
Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel
GlobeNewsWire
10 мая 2022 г. в 09:17
Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold